|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.84 INR | +1.37% |
|
+26.63% | -19.73% |
| 06-11 | Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding | CI |
| 05-27 | Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Evoq Remedies Limited reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was INR 39.03 million compared to INR 157.91 million a year ago. Revenue was INR 39.03 million compared to INR 157.91 million a year ago.
Net income was INR 0.5 million compared to INR 3.06 million a year ago. Basic earnings per share from continuing operations was INR 0.04. Diluted earnings per share from continuing operations was INR 0.04.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.73% | 1.9M | |
| +54.61% | 811B | |
| +43.70% | 640B | |
| -6.33% | 353B | |
| +20.62% | 333B | |
| +10.44% | 302B | |
| +17.94% | 246B | |
| +2.66% | 225B | |
| +12.77% | 218B | |
| +8.61% | 168B |
EVOQ REMEDIES LIMITED 
